Bertil Lindmark, an experienced developer of respiratory medicine, has been appointed chief medical officer at Vicore Pharma Holding AB to strengthen the Swedish company’s idiopathic pulmonary fibrosis (IPF) drug development. Dr Lindmark held senior positions in respiratory medicine at AstraZeneca for over 10 years including as global vice president clinical development for respiratory and inflammation where he led the development of Symbicort for asthma and COPD.
Most recently he was chief medical officer at Galecto Inc and previously head of research and development at Almirall. Dr Lindmark obtained his MD and PhD degree in molecular epidemiology from Lund University, Sweden. Vicore is developing drug candidates for lung diseases including IPF and pulmonary arterial hypertension, focusing on angiotensin II type 2 receptor agonists (ATRAGs). An interim phase 2a AIR data read-out for a drug, C21, showed potential for improving lung function in IPF.
Vicore Pharma announced the appointment on December 18, 2023.
Copyright 2024 Evernow Publishing Ltd.